• Staurosporine: Broad-Spectrum Kinase Inhibitor for Apoptosis

  2026-04-27

  Staurosporine, a gold-standard broad-spectrum serine/threonine protein kinase inhibitor, empowers cancer researchers to dissect apoptosis, kinase signaling, and angiogenic pathways with unmatched reproducibility. Explore optimized workflows, advanced experimental insights, and troubleshooting strategies for deploying APExBIO’s Staurosporine in quantitative cell death assays and anti-angiogenic studies.

• G007-LK: Potent Tankyrase 1/2 Inhibitor for Wnt Pathway Rese

  2026-04-27

  G007-LK is a highly selective tankyrase 1/2 inhibitor with nanomolar potency, enabling precise modulation of the Wnt/β-catenin signaling pathway. It is widely used in APC mutation colorectal cancer research and demonstrates robust β-catenin degradation and tumor suppression in vitro and in vivo. This article reviews its mechanism, benchmarks, and workflow integration for advanced cancer biology studies.

• Cholecystokinin Octapeptide Ammonium: A Precision Tool for I

  2026-04-26

  Explore the unique modulatory roles of Cholecystokinin octapeptide ammonium (CCK-8 ammonium) in immune and neuronal assays. This in-depth article reveals mechanistic insights, optimal protocols, and evidence-based applications distinct from existing resources.

• Optimizing Cell-Based Assays with EZ Cap™ Firefly Luciferase

  2026-04-25

  Explore how EZ Cap™ Firefly Luciferase mRNA (SKU R1018) addresses key challenges in cell viability, proliferation, and cytotoxicity assays. This article provides scenario-driven guidance on protocol design, data interpretation, and vendor selection to achieve reproducible, high-sensitivity results in bioluminescent reporter workflows.

• IWP-2: Enabling Precision Modulation of Wnt Signaling in Tra

  2026-04-24

  This thought-leadership article explores the mechanistic power and translational impact of IWP-2, a potent Wnt production inhibitor, in dissecting cellular fate and disease mechanisms. Featuring evidence from corneal regenerative research and cancer studies, it offers actionable protocol guidance, contextual product intelligence, and strategic vision for researchers seeking to translate pathway insights into clinical innovation.

• Norovirus Exploits NINJ1 for Selective NS1 Protein Secretion

  2026-04-24

  This study reveals how murine norovirus (MNoV) hijacks the host protein NINJ1 to selectively secrete its NS1 protein through an unconventional, apoptosis-linked pathway. By uncovering the molecular basis for this selectivity, the work advances our understanding of viral immune evasion and cell death regulation.

• LY294002: Applied PI3K/Akt/mTOR Inhibition in Cancer Researc

  2026-04-23

  LY294002, a potent and reversible PI3K/Akt/mTOR pathway inhibitor, is transforming experimental cancer research with its stability, specificity, and versatility. This guide details real-world workflows, protocol tips, and troubleshooting insights that empower researchers to optimize outcomes in apoptosis, autophagy, and tumor immunology studies using LY294002 from APExBIO.

• GSK J4 HCl: Applied JMJD3 Inhibition for Epigenetic Research

  2026-04-23

  GSK J4 HCl empowers researchers to precisely interrogate JMJD3-dependent chromatin regulation, with robust applications in inflammation and tumor modeling. This guide translates breakthrough mechanistic insights and experimental best practices into actionable workflows, maximizing the impact of this selective inhibitor in advanced epigenetic regulation research.

• Direct Reprogramming of Human Fibroblasts into Cardiomyocyte

  2026-04-22

  Romero-Tejeda et al. identify a novel transcription factor combination enabling efficient direct reprogramming of human cardiac fibroblasts to spontaneously contracting cardiomyocyte-like cells. Their use of high-throughput combinatorial screening, with validation of the Wnt/β-catenin pathway's modulatory role, offers new avenues for cardiac regeneration research.

• Crizotinib Hydrochloride: Advanced ALK Kinase Inhibition in

  2026-04-22

  Crizotinib hydrochloride empowers researchers to dissect oncogenic kinase signaling in physiologically relevant, patient-derived assembloid models. This guide offers stepwise workflow enhancements, troubleshooting strategies, and quantitative protocol insights for optimizing ALK and c-Met inhibition in preclinical cancer biology.

• Cdk5 Downregulation Mitigates Neuronal Ferroptosis via AMPK

  2026-04-21

  This study demonstrates that inhibiting Cdk5 activity in ischemic stroke models reverses neuronal ferroptosis by modulating the AMPK pathway and microglial polarization. The findings provide mechanistic insight into neuroprotection strategies targeting iron-dependent cell death and inflammation in the hippocampus.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Control of β-Cate

  2026-04-21

  Explore the advanced mechanistic, assay, and translational insights of the G007-LK tankyrase 1/2 inhibitor in modulating Wnt/β-catenin and Hippo pathways. This article uniquely integrates in-depth evidence, protocol guidance, and recent cross-pathway findings to enhance APC mutation colorectal and hepatocellular cancer research.

• Targeted SPP1 Inhibition in Tumor-Associated Macrophages Red

  2026-04-20

  This study introduces a phenotypic screening approach to identify small molecule modulators that suppress SPP1 expression in tumor-associated macrophages (TAMs), a key driver of tumor progression. The lead compound, delivered via a TAM-avid nanoformulation, achieved robust tumor size reduction in vivo, highlighting a novel therapeutic avenue for targeting TAMs in cancer.

• Lypressin Acetate: Applied Workflows in Vasopressor Assays

  2026-04-20

  Lypressin acetate (lysine vasopressin acetate) stands out for its dual antidiuretic and vasoconstrictive properties, enabling robust experimental modeling of GPCR signaling, vasopressor activity, and emerging antiviral targets. This guide translates recent findings and industry best practices into actionable workflows, protocol parameters, and troubleshooting strategies for researchers optimizing their peptide hormone assays with confidence.

• IGF2BP1-m6A Axis Drives Macrophage Glycolysis in Pulmonary F

  2026-04-19

  This study uncovers a mechanistic axis where the m6A reader IGF2BP1 stabilizes THBS1 mRNA, enhancing macrophage glycolysis and M2 polarization to promote pulmonary fibrosis. By detailing the IGF2BP1/THBS1/TLR4 pathway, the findings highlight novel targets for fibrosis intervention and inform metabolic and immunologic research strategies.

15578 records 1/1039 page Next 12345 下5页 Last page